We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetic Changes Linked to Leukemia in Down’s Syndrome Children

By LabMedica International staff writers
Posted on 24 Jul 2019
Print article
Image: Bone marrow aspirate of a patient with myeloid leukemia associated with Down’s syndrome. The smear includes frequent atypical megakaryocytes. Blasts are increased (11%). As in the peripheral blood, a subset of the blasts has cytoplasmic blebs (Photo courtesy of Elizabeth L. Courville, MD).
Image: Bone marrow aspirate of a patient with myeloid leukemia associated with Down’s syndrome. The smear includes frequent atypical megakaryocytes. Blasts are increased (11%). As in the peripheral blood, a subset of the blasts has cytoplasmic blebs (Photo courtesy of Elizabeth L. Courville, MD).
Of the 30% of children with Down's syndrome who are found to have 'myeloid preleukemia', only 10% of those will go on to develop myeloid leukemia (3% of all children with Down's syndrome). Until now, it was not understood why only some children with the GATA1 mutation were progressing to full leukemia, while others were not.

The specific gene mutations required for the development of leukemia in children with Down's syndrome have been discovered. Children with Down's syndrome have a 150-fold increased risk of myeloid leukemia, and while some of the genetic causes of this have been previously established, and a new study has identified a wide range of mutations and how they functionally interact to lead to leukemia.

An international team of scientists collaborating with those at the University of Oxford (Oxford, UK) combined exome and targeted resequencing of 111 transient abnormal myelopoiesis (TAM) and 141 myeloid leukemia-Downs’s syndrome (ML-DS) samples with functional analyses. TAM requires trisomy 21 and truncating mutations in GATA1; additional TAM variants are usually not pathogenic. By contrast, in ML-DS, clonal and subclonal variants are functionally required.

The scientists identified a recurrent and oncogenic hotspot gain-of-function mutation in myeloid cytokine receptor CSF2RB. By a multiplex CRISPR/Cas9 screen in an in vivo murine TAM model, they tested loss-of-function of 22 recurrently mutated ML-DS genes. Loss of 18 different genes produced leukemias that phenotypically, genetically, and transcriptionally mirrored ML-DS.

Paresh Vyas, MRCP FRCP FRCPath, a Professor of Hematology and a study author, said, “90% of babies with Down's syndrome do not go on to develop preleukemia. But until now, we did not fully understand why some babies did develop leukemia. 'To answer this question, we carefully characterized the mutations in genes required for leukemia to develop. We found that additional genetic changes are required in the altered GATA1 blood cells, and these additional changes transform the preleukemic blood cells into leukemic blood cells.” In total, 43 different altered genes were found. The study was published on July 11, 2019, in the journal Cancer Cell.

Related Links:
University of Oxford

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.